Neural Substrates of Emotion Regulation in Premenstrual Dysphoric Disorder

描述（由申请人提供）：经前焦虑症（PMDD）是经前综合征的一种严重变体，影响2-5%的育龄妇女，生活质量下降与重度抑郁症中观察到的生活质量下降相当（Epperson et al.，2012; Halbreich等人，2003; Wittchen等人，2002年）。然而，这种疾病的研究不足，PMDD的治疗受到缺乏神经生物学基础知识的阻碍。情感症状，如易怒/愤怒，抑郁，情绪波动，焦虑，出现在黄体期，表明情绪调节的问题可能有助于疾病，但我们知道没有研究的情绪调节与PMDD的妇女。我们假设，在神经回路介导的情绪调节功能障碍是一个重要的贡献者的情感症状的PMDD。 这个项目的主要目的是测试这个想法，使用功能性磁共振成像（fMRI）， 在患有PMDD的女性和没有这种疾病的对照参与者中。两组女性（每组n=18）将接受功能磁共振成像，同时执行验证的任务，涉及情感唤起图像的呈现，以及故意和偶然的负面情绪反应的调节。测试将在月经周期的黄体晚期进行，当PMDD症状发生时，以及卵泡期。该项目的成功将有助于阐明PMDD症状的病因，并为评估改善这种疾病的行为和药物干预提供生物标志物。

DESCRIPTION (provided by applicant): Premenstrual dysphoric disorder (PMDD), a severe variant of premenstrual syndrome, affects 2-5% of women in their reproductive years, with decreases in quality of life comparable to those observed in major depressive disorder (Epperson et al., 2012; Halbreich et al., 2003; Wittchen et al., 2002). The disorder is nonetheless understudied, and treatment of PMDD is hindered by a lack of knowledge regarding its neurobiological basis. Affective symptoms, such as irritability/anger, depression, mood swings, anxiety, which appear in the luteal phase, suggest that problems with emotion regulation may contribute to the disorder, but we are aware of no study of emotion regulation in women with PMDD. We hypothesize that dysfunction in the neural circuitry that mediates emotion regulation is an important contributor to the affective symptoms of PMDD. The primary objective of this project is to test this idea, using functional magnetic resonance imaging (fMRI), in women with PMDD and comparison participants without the disorder. Two groups of women (n=18 per group) will undergo fMRI while performing validated tasks that involve presentation of emotionally evocative images, and the intentional and incidental regulation of negative emotional response. Testing will be done during the late luteal phase of the menstrual cycle, when PMDD symptoms occur, and the follicular phase. Success in this project will help clarify the etiology of the symptoms of PMDD, and provide biomarkers for assessing behavioral and pharmacological interventions to ameliorate this disorder.